Enevate Named Triple CES 2018 Innovation Awards Honoree
Enevate Corporation, a lithium-ion (Li-ion) battery technology company, has been named a Consumer Electronics Show (CES) 2018 Innovation Awards Honoree in three categories—Vehicle Intelligence & Self-Driving Technology, Eco-Design and Sustainable Technologies, and Tech for a Better World—for its groundbreaking silicon-dominant Li-ion battery technology. This technology allows Electric Vehicles (EVs) to extreme fast charge in 5 minutes with uncompromised range and safety.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171114005548/en/
Enevate’s HD-Energy Technology for Electric Vehicles recognized for three Consumer Electronics Show 2018 awards (Graphic: Business Wire)
Enevate’s HD-Energy® Technology for EVs allows batteries to be charged in 5 minutes to 75% capacity. They can also safely charge and discharge down to -40°C and capture more energy during regenerative braking, extending their range in cold climates. With this technology, batteries are inherently resistant to lithium-plating during fast charge and in low temperatures, which is a key safety benefit.
“We are thrilled to be named a CES Innovation Award Honoree, and that our breakthrough HD-Energy Technology for EVs is being recognized in three categories,” said Jarvis Tou, Executive Vice President of Marketing and Products at Enevate. “This new extreme fast charge technology breaks down the barriers to EV adoption for a cleaner and better world. With our silicon Li-ion battery technology, EVs can be charged in 5 minutes to ease drivers’ range anxiety, while providing short charge times and low cost.”
Enevate’s HD-Energy Technology for EVs is available for licensing. Cells made using Enevate’s HD-Energy Technology for Electric Vehicles (EVs) will be displayed at CES 2018 in the Innovation Awards Showcase, which runs January 9-12, 2018, in Las Vegas, Nevada. CES 2018 Innovation Honoree products are featured on CES.tech/Innovation.
The prestigious CES Innovation Awards are sponsored by the Consumer Technology Association (CTA)™, the owner and producer of CES 2018, the global gathering place for all who thrive on the business of consumer technologies, and have been recognizing achievements in product design and engineering since 1976. Products and technologies entered in this prestigious program are judged by a preeminent panel of independent industrial designers, independent engineers and members of the trade media to honor outstanding design and engineering in cutting edge consumer electronics products across 28 product categories.
Enevate Corporation, with global headquarters in California USA, develops and licenses advanced silicon-dominant Li-ion battery technology that revolutionizes the electric vehicle (EV) market by breaking down barriers to EV adoption. Enevate's pioneering work on silicon-dominant anodes and cells has resulted in its breakthrough HD-Energy® Technology featuring extreme fast charging with uncompromised high energy density, excellent low-temperature operation for cold climates, and safety advantages over conventional graphite Li-ion batteries.
Investors include Mission Ventures, Draper Fisher Jurvetson, Tsing Capital, Infinite Potential Technologies, Presidio Ventures – a Sumitomo Corporation company, CEC Capital and strategic investors. To learn more about or to license Enevate’s industry-defining battery technology, visit www.enevate.com.
Lynn Lewis, 480.775.8880
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection14.11.2018 23:07 | Tiedote
SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD). The trial assessed patients using the Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and disc height via MRI scans. Using composite scoring, 54% of the treatment arm patients met all three endpoints as compared to only 17% with the placebo (p=0.0003). Over 84% of patients in the treatment group of CybroCell™ or CybroCell™ with platelet rich plasma (PRP) injections had an increase or no change in disc height compared to 25% for the placebo saline injection. Analyzed individually, 83% of spinal discs that were injected with CybroCell™ had an increase or no change in disc he
Raising Awareness about Early Onset Dementia: “Don’t Leave me now”, Written by Brian Daniels14.11.2018 19:55 | Tiedote
The Fondation IPSEN is delighted to invite you to a theatre performance about familial upheavals when a family member is affected by Alzheimer’s disease or cerebral dementia (November 21 st at 4pm). This play has been written by playwright Brian Daniels and directed by Jeni Draper, has had more than 200 performances and explores with insight and humour the impact of early onset dementia on family life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005695/en/ (Graphic: Business Wire) Free entrance, but registration is mandatory (limited seats): Please click here NOVEMBER 21 st , 4 pm “Le Petit Théâtre de la Fondation IPSEN” 65 quai George Gorse 92150 Boulogne-Billancourt (Metro Line 9, Pont-de-Sèvres) About the Project Our “Science for People” program is composed of accessible meetings and webinars to improve access to science. Brian Daniels’ play “Don’t leave me now” is about caregivers of people with Alzheimer’s Dise
HCL Technologies Celebrates 10 Years of Success in the Nordics14.11.2018 19:44 | Tiedote
HCL Technologies (HCL), a leading global technology company, is celebrating its 10-year anniversary in the Nordic region. During this time, the company has achieved significant successes, which have seen the Nordics grow to become HCL’s largest market in Europe. Today, HCL employs more than 1,600 people in the Nordics representing 31 nationalities, with 55 large-scale transformational clients including four out of the six Fortune Global 500 companies in the region. While several significant milestones have been successfully achieved, HCL looks forward to the future and is dedicated to helping its clients in the Nordics to drive innovation and growth. The celebration coincides with a series of initiatives to mark this occasion starting with the opening of a new office at HCL’s Nordics headquarters in Central Stockholm. “We are humbled by the success that we have achieved together with our clients, colleagues and partners in the Nordics,” said Pankaj Tagra, EVP Nordic and DACH Head, HCL
The Next Industrial Transformation is Here: Rockwell Automation is Helping Businesses Prepare to Succeed at Automation Fair 201814.11.2018 19:35 | Tiedote
Today, at its annual Automation Fair, Rockwell Automation unveiled its new brand promise: Expanding Human Possibility by combining the imaginations of people with the intelligence of machines. The brand promise supports the company’s emphasis on bringing The Connected Enterprise to life and how, by linking people, machines and data across an entire business, manufacturers become more effective and productive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005671/en/ Blake Moret, chairman and CEO, Rockwell Automation, shares his vision for bringing the Connected Enterprise to life and how manufacturers can expand human possibility by linking people, machines and data across their businesses, helping them to become more effective and productive. (Photo: Business Wire) “The new Rockwell Automation brand emphasizes the central role that people play in advanced manufacturing and underscores our focus on ways we maximize per
Hospital in Cox’s Bazar Will Offer 24/7 Medical Aid to 140,000 Rohingya Refugees14.11.2018 18:53 | Tiedote
A 100-bed capacity hospital opened in Cox’s Bazar district in Bangladesh. It is expected to serve 140,000 Rohingya refugees based in the Kutupalong camp. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005631/en/ Sheikh Sultan bin Ahmed Al Qasimi, humanitarian envoy of the foundation and chairman of SMC inaugurated the hospital last Friday. (Photo: Business Wire) This round-the-clock medical facility, built and managed by Médecins Sans Frontières (MSF) – Doctors without Borders with the support of Sharjah-based international humanitarian organisation, The Big Heart Foundation (TBHF), aims to treat 7,200 people in its first year. Part of TBHF’s leading humanitarian efforts to reach out globally to vulnerable communities, this hospital project was supported by AED 3 million donation from Sharjah Media Corporation (SMC), through its public fundraising initiative on healthcare projects, and will offer much-needed relief to
Janssen Seeks Expanded Use of IMBRUVICA®▼ (ibrutinib) in Two Indications in Europe14.11.2018 17:23 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two Type II variation applications to the European Medicines Agency (EMA) seeking approval for the expanded use of IMBRUVICA® (ibrutinib). One application seeks to include use of ibrutinib in combination with obinutuzumab in previously untreated adults with chronic lymphocytic leukaemia (CLL) and to add long-term follow-up data from the existing label studies RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115). The second is for use of ibrutinib plus rituximab for the treatment of previously untreated and relapsed/refractory adults with Waldenström's macroglobulinemia (WM). “Today’s news brings us one step closer to potentially offering ibrutinib in new combinations for patients where unmet needs still persist,” said Dr. Catherine Taylor, Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag Limited. “Ibrutinib continues to demonstrate clinical benefit over the long
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme